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Abstract: There has been an increasing focus on development of new routes of drug 
administration to provide tailored treatments for patients, without decreasing efficacy of 
analgesia, in proportion to the progression of the knowledge of pain mechanisms. While acute 
pain acts as an alarm, chronic pain is a syndrome requiring meticulous selection of analgesic 
drugs of high bioavailability for long-term use. Such criteria are challenges that topical 
medications aim to overcome, allowing progressive delivery of active component, maintaining 
stable plasma levels, with a good safety profile. This review presents recent findings regarding 
topical formulations of the most widely used drugs for pain treatment, such as nonsteroidal 
anti-inflammatory agents, anesthetics, and capsaicin, and the role of physical agents as delivery 
enhancers (phonophoresis and iontophoresis). Although the number of topical agents is limited 
for use in peripheral conditions, increasing evidence supports the efficacy of these preparations 
in blocking nociceptive and neuropathic pain. Patient adherence to medical treatment is also 
a challenge, especially in chronic painful conditions. It is known that reduction of treatment 
complexity and pill burden are good strategies to increase patient compliance, as discussed 
here. However, the role of topical presentations, when compared to traditional routes, has not 
yet been fully explored and thus remains unclear.
Keywords: medication adherence, administration, topical, patient compliance, pain, 
therapeutics
Introduction
The International Association for the Study of Pain defines pain as a multidimensional 
entity that involves nociception, afferents to the central nervous system, modulation, 
affective responses, endogenous analgesia, behavioral adjustments, and changes of 
social roles. While pain trigger factors are endured, pain degenerates to an independent 
response, manifesting even when it is possible to eradicate the primary stimulus.
Despite technological advances and thorough established treatments, chronic pain 
continues to defy health professionals, because it is a poorly controlled condition;1 
partly because there are three aspects involved in the pathogenesis of pain: nociception 
(pain sensation and topography), emotional (fear and depression), and behavioral 
factors (catastrophism, vigilance, and somatic awareness). Pain management faces 
difficulties that restrict therapeutic success, such as the limited efficiency of analgesics, 
systemic effects, and cognitive impairment of drugs due to central effects.
As the understanding of pain pathophysiology and treatment increases, new routes 
of drug delivery are being discovered with the objective of attempting to block pain Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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at peripheral sites, with maximum active drug and minimal 
systemic effects. Topical preparations are the result of such 
exploration.
For patients, the rationale is the application of analgesics 
directly on the site of soreness, even if the sensation is a 
referred pain from another source. They perceive that oral 
treatments can potentially lead to more adverse effects as com-
pared to topical treatment. In addition, the intention of applying 
localized treatment within the lay population may be a means 
of enhancing the efficacy of the placebo element of topical 
analgesia. Such mechanisms are of limited value if the area 
of soreness is large, such as an entire limb in sympathetically 
maintained pain syndromes, and overall, placebo interven-
tions do not seem to be involved in important clinical effects. 
Nevertheless, it is well known that placebo interventions may 
influence reported outcomes, especially pain, nausea, and other 
subjective complaints that are subject to context.2
On the other hand, physicians are aware that chronic pain 
is a complex syndrome involving peripheral and central fac-
tors, justifying the prescription of multimodal therapies and 
drugs of central action.
Evidence based on empirical practice has suggested that 
topically applied medications can be almost as effective as 
those taken orally, with a good safety profile in terms of 
adverse effects. The ultimate goal that motivates the develop-
ment of topical preparations is the improvement of patient 
compliance to medical treatment, by providing efficient pain 
relief with less central nervous system effects and minimal 
drug regimen burden. Topical preparations can potentially 
benefit the pediatric population, whose chronic pain manage-
ment is just as challenging as in adults.
Topical analgesics or anesthetics are defined as liquids, 
gels, powders, creams, semisolids, emulsions, patches, 
foams, or aerosols containing an analgesic or anesthetic agent 
applied on or around the painful site. Most topical prepara-
tions are available as patches, ointments, or creams, and this 
review will focus on cutaneous applications for adult patients, 
although some studies in children are also mentioned.
Topical preparations and topical 
delivery systems
Among the most widely known drugs with peripheral 
effects are nonsteroidal anti-inflammatory drugs (NSAIDs), 
anesthetics, capsaicin, alpha-adrenoreceptor antagonists, and 
cannabinoids. However, not all medications applied topi-
cally on the skin have peripheral action. Topically applied 
opioids predominantly have a central effect. Therefore, one 
can didactically distinguish transdermal medication such as 
buprenorphine and fentanyl and topical drugs acting locally, 
which have a primary role on the peripheral nervous system 
and decrease of nociceptive afferents (Figures 1 and 2).3
Several adjuvants such as viscosity and permeation 
enhancers, emollients, and preservatives are added to the 
active component, with the objective of reducing the drug 
concentration, increasing the absorption, maintaining the 
drug at the target site, and warranting less toxicity, less 
clearance, and greater analgesic effect.4 Topical preparations 
are believed to avoid issues associated with oral or intrave-
nous routes such as gastric disturbances, first-pass hepatic 
metabolism, and variable serum concentrations. In addition, 
systemic absorption can be reduced without compromising 
the desired effect.
However, several items must be considered regarding 
topical preparations. Marked interindividual variability 
of skin properties may influence percutaneous absorption 
and distribution of the drug when applied topically, since 
the stratum corneum is a barrier that limits penetration 
of substances. The therapeutic effects also depend on the 
rate, amount, and depth of penetration into the skin and 
the potential toxicological hazards of drugs. High doses of 
sensitizing molecules cannot be administered or diffused 
into skin, and topical preparations should be water soluble 
and have an affinity for lipids. Besides, the amount of vari-
ability of individual metabolic properties directly influences 
bioavailability and needed doses or precautions. This is of 
special interest when a well-established preparation used in 
an adult population is used for children in an off-label or 
unlicensed fashion.
Physical agents such as electricity (a system called ionto-
phoresis) and ultrasound (phonophoresis) are progressively 
used as enhancers to increase permeability and delivery of 
substances into and through the stratum corneum. Despite their 
popularity, questions remain regarding definitive treatment.
Iontophoresis is the application of high-voltage pulses to 
the skin. The method enhances transdermal delivery of spe-
cific drugs, migrating charged particles across membranes. 
Figure 1 Topical patch.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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The target can be either local/focal or have systemic effects, 
and chemical enhancers can be associated. Electrical applica-
tion is well tolerated in vivo, but can induce muscle contrac-
tions. Skin irritation is a common adverse effect.
Phonophoresis is the use of ultrasound waves to enhance 
drug penetration via heating properties. The effectiveness 
of ultrasound is reduced when used for muscle spasms or 
when circulation to the area is disrupted, since its mecha-
nism of action depends on vasodilation and increase of local 
metabolism.5 Phonophoresis at an intensity of 1–3 W/cm2 
and frequency of 1 MHz for 30 min is able to better enhance 
ketorolac permeation when compared to 1–2 W/cm2. Shorter 
application periods (5 min as described in several protocols) 
provide nonsignificant effects when compared to ultrasound 
only. A continuous ultrasound mode is more effective in 
promoting drug transport than a pulsed mode. However, there 
are reports of tissue destruction or patient intolerance using 
30-min applications with stationary ultrasound.6,7
In order to maximize the clinical effectiveness of phono-
phoresis, skin must be adequately hydrated, preheated, and 
shaved for ideal ultrasound transmission. Previously applied 
ultrasound enhances the percutaneous penetration of agents.
A technique associating regional hypothermia and ion-
tophoresis improved bioavailability of sodium diclofenac 
and prednisolone in synovial fluid.8 Other results in animal 
models suggest the therapeutic antinociceptive effect of 
diclofenac depends on the current density but not on the 
application time, and that direct iontophoresis application 
to the inflamed knee of rats enhanced the therapeutic effect, 
probably because of direct delivery of the drug.9 Both ionto-
phoresis and phonophoresis of naproxen are equally effective 
electrotherapy methods in the treatment of chronic musculo-
skeletal conditions, such as lateral epicondylitis.10
Other popular devices are biodegradable implantable 
controlled drug delivery systems, which claim to offer 
good control of pain, as they continuously apply substances 
to tissue. Fewer fluctuations of serum levels of drugs are 
considered to induce less adverse effects with greater patient 
compliance.
Opioids
The analgesic effects of opioids are well known, and the two 
most described are buprenorphine and fentanyl. Despite their 
transdermal application, the effects are primarily central. 
Recent research demonstrated the presence of mu and delta 
opioid receptors at the endings of sensory afferent neurons. 
Clamping the sciatic nerve in animals caused an inflammatory 
response, resulting in an accumulation of beta-endorphinergic 
receptors at both sides of the ligature. In human models, 
topical morphine promoted relief of mucositis-related pain 
among patients undergoing head and neck chemotherapy.11 
However, other studies have failed to demonstrate benefits 
from the topical use of opioids administered for skin ulcer 
and dental procedures and painful hypertonic bladder.12
Buprenorphine
Buprenorphine is of special interest, due to its long period 
of action and antihyperalgesic effects and is free of renal 
involvement. It is a semisynthetic opioid available in inject-
able, sublingual, and transdermal presentations (BuTrans). 
The Buprenorphine patch is used for treatment of moderate 
to severe cancer pain, but it also seems to induce dose-
dependent relief for musculoskeletal pain. Demonstration 
of peripheral opioid receptors in inflamed synovia supports 
the concept of peripheral opioid analgesia. Indeed, some 
studies demonstrated the short-term analgesic effect of intra-
articular administration of buprenorphine 100 µg after knee 
arthroscopy, whose efficacy was noninferior to bupivacaine 
0.25%.13 Lower doses of buprenorphine do not produce a 
similar effect.14 Although promising, this area must be elu-
cidated continuously by additional research.
The drug differs from other opioids because of its action 
as a partial agonist of mu, delta, and kappa receptors and 
is a complete agonist of opioid receptor-like 1 receptors.15 
Buprenorphine is antihyperalgesic, partially due to its agonistic 
effect on kappa receptors, which explains the successful out-
come with neuropathic pain and syndromes presenting overt 
central sensitization. Indeed, there is evidence that neuropathic 
pain is relatively insensitive to morphine-like mu opioids.
Clinical trials indicate greater pain relief, improvement of 
sleep quality, and decreased need for rescue therapy, when 
buprenorphine is used for cancer pain.16
Transdermal buprenorphine matrix allows slow release 
for up to 96 h. Metabolism is independent of the patient’s age, 
and the drug is not immunosuppressive. Buprenorphine does 
Figure 2 Opioid transdermal patch.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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not antagonize or cause tolerance when combined with pure 
microagonists delivered as rescue medication. Its long period 
of action and relatively safe profile renders buprenorphine 
as a good option for older patients or those presenting with 
renal impairment. The analgesic effect is satisfactory for 90% 
of patients monitored for 7.5 months. Generally, tramadol, 
sublingual buprenorphine, or paracetamol combinations are 
used in clinical practice when additional pain relief is needed. 
Among these subjects, more than half reported successful 
analgesia using one patch with one supplementary daily 
rescue, indicating low occurrence of tolerance.
Initially, buprenorphine use was not widespread, due 
to safety issues noted in animal studies. Recently, clinical 
trials demonstrated attractive drug characteristics for its 
use in chronic pain, such as relative safety with respiratory 
depression and renal dysfunction, when compared to opioids 
such as hydromorphone, methadone, morphine, and fentanyl. 
The most frequently reported side effects (dizziness, nausea, 
vomiting, constipation, fatigue, and pruritus) are well toler-
ated with dose adjustment.17 No ceiling dose is described, 
only the limit posed by adverse respiratory depression. There 
is a lack of antagonism with other pure mu opioids, thus can 
be combined safely and effectively. The interchange between 
oral morphine and buprenorphine leads to pain relief in 
managed doses, but the definitive equipotency ratio has not 
yet been established. It has been suggested that approximate 
equianalgesic ratios of transdermal buprenorphine compared 
to oral morphine and oral oxycodone are around 1:110, and 
that of transdermal fentanyl to oral morphine are in the range 
of 1:75.16
Despite the absence of a difference in side effect profiles 
when comparing transdermal opioids and oral slow-release 
morphine, the former leads to significantly less constipation 
rates.18
Fentanyl
Fentanyl is a high-potency synthetic pure agonist opioid, 
which interacts with mu opioid receptors. The low molecular 
weight and lipid solubility enable it to be delivered by the 
transdermal route. Its principal use is for chronic cancer pain, 
and since the 1990s, it has also been used for some cases 
of nonmalignant pain.19 For functionally impaired patients 
with nociceptive pain secondary to osteoarthritis who are 
ineligible to take other drugs, a systematic review suggests 
opioids are more effective than control interventions. 
However, side effects can be substantial, considering that 
the target population is elderly and present with chronic 
comorbidities. Because risks are higher than benefits, opioids 
are not recommended for routine treatment of osteoarthrosis, 
even if pain is severe.20
Fentanyl is in the marketplace as a patch (transdermal 
route, Duragesic®; Alza Corporation, Mountain View, CA; 
Janssen Pharm Inc., Titusville, NJ), nasal spray, inhaler, lol-
lipop, as well as buccal tablet for transmucosal absorption. 
Transdermal administration provides long-term analgesia, 
by releasing fentanyl into the bloodstream within 48–72 h, 
with some variability depending on factors such as skin type, 
amount of body fat, different manufacturers, and placement 
of the patch. The patch is available in a variety of sizes and 
dosages (12.5, 25, 50, 75, and 100 µg/h). Fentanyl 12.5 µg/h 
is suitable for moderate pain and the pediatric palliative 
population.
The nasal route of presentation results in a rapid response, 
but evidence is scarce and there are concerns related to safety 
and cost.
The fentanyl membrane patch matrix has a low drug 
concentration, aiming to increase safety and avoid the fen-
tanyl-containing gel present in traditional fentanyl reservoir 
patches. This silicon matrix with a controlling membrane 
contains the drug and provides slow release at a constant rate. 
Matrix fentanyl was not inferior to gold-standard opioids for 
pain relief during 30-day follow-up of cancer patients. They 
reported good tolerance of side effects such as dizziness, 
somnolence, and constipation.21
A patient-controlled fentanyl iontophoretic transdermal 
system (ITS) (Figure 3) is approved by the US Food and Drug 
Administration (FDA) for the management of acute postsur-
gical pain. It provides self pain control to patients without 
fluctuations in analgesia, in contrast to the traditional fentanyl 
patch, which releases the drug at fixed rates within 72 h and 
was designed for use in chronic pain. The device comprises 
an electrical field of 170 mA that actively allows diffusion 
of ionized fentanyl hydrochloride through intact skin into 
bloodstream, at a 40-µg dose in 10 min. The credit card-sized 
equipment does not require needles and is preprogrammed, 
eliminating the risk of bleeding, catheter infiltrations, and 
management errors. Fentanyl ITS and intravenous fentanyl 
differ in 1-h plasma concentration, which are 0.1 and 0.7 ng/
mL, respectively. ITS absorption is time-dependent within 
the first 10 h of dosing. This delivery technology is superior 
to placebo, and it is equivalent to patient-controlled morphine 
analgesia (PCA).22,23 In pediatrics, one must note that the time 
to achieve plasma steady state and clearance are longer, and 
elimination is faster. For children, studies verifying supe-
riority of fentanyl over morphine are rare, and randomized 
controlled trials in the pediatric population are still lacking. Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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However, the drug is being used off label or unlicensed with 
increasing frequency as a promising option.24 Despite the 
paucity of clear regulatory guidelines, parents and medical 
professionals appear to be satisfied with fentanyl ITS.
The transdermal fentanyl system with a drug release rate 
of 12.5 µg/h matches the lower dosing requirements for pain 
relief in children. Time to reach steady state serum drug 
concentrations is longer, clearance is higher, and half-life 
elimination is shorter in children than in adults. A conversion 
factor of 45 mg/day oral morphine to 12.5 µg/h transdermal 
fentanyl is used for initial therapy dose estimation in chil-
dren receiving long-term morphine therapy. Children may 
take longer to reach stable fentanyl serum concentrations 
than adults, and younger children require higher doses than 
adults.24 In an attempt to provide more flexible dosing for 
pain management in children, some encourage the use of 
partially occluded fentanyl patches. However, this technique 
requires further tests in clinical practice.25
Adverse effects have been observed with pure opioid 
agonists. The most common are nausea, vomiting, headache, 
and erythema, with low rates of respiratory depression. When 
comparing children and adults, the profile of adverse effects 
is similar. Increasing doses lead to respiratory impairment, 
corresponding to plasma concentrations above 1.4–2.5 ng/mL. 
Excessive use of iontophoretic fentanyl and abuse can lead to 
death. Fentanyl resulted in less constipation when compared to 
morphine, both in adults and in children. Strategies to minimize 
long-term adverse effects of opioids include dose monitoring, 
opioid rotations, and change of administration routes.
Anesthetics
Anesthetic creams have been developed to counteract the 
discomfort related to venipuncture and intravenous catheter 
insertion in hospitalized children and adults. In fact, blood 
draws are the most frequently reported painful events.
Despite the clear demand for topical anesthetic drugs in 
hospital settings and the fact that application of anesthetic 
creams are painless in comparison to anesthetic infiltrations, 
the former remains in disuse, partly due to the long onset of 
action and inconsistent effectiveness reported. For utility in 
practice, a topical anesthetic must be easy to apply, have few 
side effects, not require specialized equipment, and have a 
low cost. Transdermal technologies that promote the flow 
of several sizes of molecules through the skin barrier via 
the creation of transient microchannels are able to provide 
greater anesthesia in ,20 min.26
Many anesthetics are available in gel, cream, or patch. 
A widely used product is the eutectic mix of lidocaine 
2.5% and prilocaine 2.5% (EMLA® cream-2 ; Astra Zeneca 
Pharmaceuticals, Wilmington, DE; APP Pharmaceuticals, 
Schaumburg, IL). It has been employed as a cutaneous anes-
thetic applied before invasive procedures and empirically for 
the treatment of postherpetic pain. However, the US Food 
and Drug Administration has not approved it for treatment 
of neuropathic pain. No safety studies on long-term use of 
topical anesthetics were found in the literature. Methemo-
globinemia has been associated with prilocaine. There are 
reports of lidocaine patch and EMLA cream-induced allergic 
contact dermatitis, suggesting that prilocaine and the vehicles 
propylene glycol and parabens may act as immunogens.
Ametop® (Smith & Nephew Healthcare Ltd, London, UK) 
is a tetracaine base 4% water-in-water gel that has been used 
extensively in adults and children for cutaneous pain related 
to procedures. A meta-analysis of 534 children comparing 
amethocaine with EMLA that evaluated anesthetic efficacy, 
ease of needle insertion, and resultant skin changes showed 
that despite the known efficacy of EMLA as a topical anes-
thetic for children, amethocaine was superior in reducing 
pain following needle insertion procedures.27 EMLA and 
Ametop are examples of pediatric evidence being extrapo-
lated for application in adults. However, this translation into 
adult clinical practice must be done cautiously, because of 
the known differences of skin thickness, pharmacokinetics, 
and metabolism between these two populations.
A systematic review verified the efficacy of EMLA 
plasters for analgesia during debridement or dressings. The 
mixture provided significant relief, but the effect on tissue 
healing remains obscure. There is no evidence regarding 
Figure  3  iontophoretical  transdermal  system  (iTS).  iTS  delivers  drug  into  the 
bloodstream, and includes: anode hydrogel (ionized drug reservoir), cathode (inert 
ingredients), battery, and protective plastic liner.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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the advantage of the use of EMLA on persistent pain 
following chronic venous insufficiency.28
Recently, a patch containing lidocaine 70 mg and 
tetracaine 70 mg (Rapydan® in Europe [EUSA Pharma Inc., 
Oxford, UK] and Synera® in USA [Endo Pharmaceuticals 
Inc., Ford, PA]) combined with a controlled heat-assisted drug 
delivery system for fast onset of action has been FDA- and 
European Medicines Agency-approved for pain relief during 
needle punctures, cannulations, and other superficial surgical 
procedures. The drug combination is indicated for surface 
anesthesia of normal intact skin in children aged above 3 years 
and in adults. When compared to EMLA in controlled clinical 
trials, the novel patch provided effective anesthesia with an 
application time of 10 min. Data suggest that the lidocaine/
tetracaine patch may represent an important alternative to 
lidocaine/prilocaine cream for topical local anesthesia before 
vascular access among adults29 and children.30
Other topical drugs such as a combination of tetracaine, 
adrenaline, and cocaine (TAC) have been tested for anal-
gesia during procedures in children. However, their use is 
not supported in the literature because of toxicity and the 
availability of superior alternative drugs. Other combinations 
such as lidocaine, epinephrine, and tetracaine (LET), as well 
as bupivacaine plus norepinephrine, were effective for scalp 
analgesia during repair of lacerations.
Lidocaine
Lidocaine blocks voltage-gated sodium channels, and topical 
administration is believed to hush ectopic discharges of fine 
afferent fibers. It was recognized that a lidocaine patch acted 
only on abnormal, intact hyperalgesic afferent receptors. 
Recently, patches proved to be effective also in skin devoid of 
nociceptors.31 Topical lidocaine slows peripheral nociceptor 
sensitization and central hyperexcitability. Patients presenting 
with concurrent allodynia were the most extensively studied 
in clinical trials, but analgesic benefits were also observed in 
patients presenting with nonallodynic neuropathic pain.
Lidocaine is available in 5% patches (Lidoderm®; Endo 
Pharmaceuticals Inc.,) and is approved in the USA for pos-
therpetic neuralgia treatment and other focal neuropathic 
syndromes (mononeuropathies, intercostal neuralgias, and 
postamputation pain) in which traditional treatment using tri-
cyclic antidepressants, anticonvulsants, and opioids fail.32–34 
Nevertheless, topical lidocaine should only be prescribed as 
a second-line agent for postherpetic neuralgia.35
Positive effects on quality of life scales and pain are sup-
ported by several clinical trials, where up to three applications 
were noted in 12 h.
Several pharmacokinetic studies demonstrated that 
systemic absorption of the lidocaine patch in healthy adults is 
minimal when up to four units are applied with 12–24-h/day 
dosing; absorption rate is lower among postherpetic neuralgia 
patients, who benefit from a pure lidocaine patch or combined 
with other agents. No drug–drug interaction was observed, 
and its use does not result in a beta-mediated sensory loss at 
the application site.
Topical anesthetics (lidocaine 5% ointment, pramoxine 
hydrochloride 1% with hydrocortisone acetate 1% in water 
miscible mucoadhesive foam base, alcoholic lignocaine 5% 
spray, lignocaine 1%–5% gel, and cinchocaine 2%) were 
studied for the relief of perineal pain after vaginal delivery. 
However, evidence of effectiveness and long-term effects 
were inconclusive.36
There are reports of increase in skin blood flow and 
vascular reactivity with the use of EMLA and a warmth-
producing lidocaine/tetracaine patch, which could enhance 
visibility of veins and improve success rate with punctures. 
Nevertheless, the hyperemic response is transient, with 
possibly a stronger effect with Rapydan as compared to 
EMLA.30,37
There is anecdotal evidence from an open-label, non-
randomized trial that lidocaine 5% patches were safe and 
effective for subacute and chronic low back pain when used 
daily for 6 weeks.38
The side effects were mild and clinically irrelevant, such 
as skin irritation.39 Due to the safety profile, low incidence 
of systemic effects, and low probability of interactions with 
other drugs, the lidocaine patch is considered to be a suit-
able treatment for focal neuropathic pain, with or without 
allodynia, also for the elderly.40
NSAiDs
NSAIDs are popular drugs and have widespread use for 
chronic and acute musculoskeletal conditions. They have the 
advantage of local action without developing central adverse 
effects and cognitive impairments. Side effects have been 
well described, although partly neglected.
Within the NSAID class, each drug has a specific tissue 
distribution and pharmacodynamics. They block the inflam-
matory cascade and cyclooxygenases (COX) by inhibiting 
prostaglandin and thromboxane production and lead to 
reduction in pain, fever, platelet aggregation, and inflam-
matory response.41
The goal of topical NSAIDs is to minimize systemic 
adverse effects and encourage compliance. Topical NSAIDs 
are presented as gel, cream, or spray, to penetrate through Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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skin, adipose tissue, and muscles, in sufficient dose to induce 
peripheral effects without plasma concentration.
Comparison and evaluation of topical NSAIDs are dif-
ficult due to the diversity of presentations of the marketed 
drugs and variety of methods used in the trials. Overall, 
when NSAIDs are applied topically, a high concentration 
is observed in the dermis and muscles (equivalent to that 
obtained with oral route), with less gastrointestinal effects. 
Plasma concentrations are 5%–15% of those achieved by 
systemic delivery. In joints, evidence is less robust and 
suggests that topically applied NSAIDs reach the synovia. 
Either topical penetration or distribution via systemic 
circulation could be involved; however, the mechanism 
remains unclear.
A systematic review of topical NSAIDs for acute mus-
culoskeletal conditions (such as strains and overuse-type 
injuries) studied 3455 subjects and concluded that the 
preparations can provide good levels of pain relief, without 
the systemic adverse events associated with oral NSAIDs. 
Positive outcomes were observed with use of diclofenac, 
ibuprofen, ketoprofen, and piroxicam.42
Substantial data also suggest that topical NSAIDs have 
pain-relieving properties in chronic rheumatic diseases. Per-
haps an important sign of the increasing importance of using 
topical medication is that the European League against Rheu-
matism and the International Osteoarthritis Research Society 
state that topical NSAIDs are preferred over oral NSAIDs for 
mild-to-moderate pauciarticular hand and knee osteoarthritis, 
in patients with sensitivity to oral compounds.43 In addition, 
the UK NICE guidelines for knee and hand osteoarthritis 
recommend use of paracetamol and/or topical NSAIDs over 
oral NSAIDs, COX2 inhibitors, and opioids.44
Many NSAIDS are sold over-the-counter, representing 
a clear risk for patients. Another major concern regarding 
topical NSAID use is the risk of overdosing by applying 
several preparations at the same time.
Ketorolac tromethamine gel solution was tested for pho-
nophoretical transdermal delivery using pulsed ultrasound 
in an in vitro inflammatory pain model (cellulose and rab-
bit skin membranes). Antihyperalgesic effects were noted 
when compared to topical application only. When ibuprofen 
5%, piroxicam, and diclofenac were tested via phonopho-
resis, diclofenac had the smallest flow and permeability 
coefficient.45
Diclofenac
This drug has antipyretic and anti-inflammatory actions, with 
greater COX2 inhibition when compared to indomethacin 
or naproxen. It has been approved for the treatment of rheu-
matoid arthritis, acute postsurgical pain, and dysmenorrhea, 
among other conditions. Adverse effects on gastrointestinal 
and cardiovascular systems are similar to celecoxib. Other 
effects include allergies, rash, and renal impairment.
It has high absorption, urinary excretion, a half-life of 
1–2 h and can concentrate in synovial fluid after oral admin-
istration, which explains long-term effects even when drug 
concentration in plasma diminishes.
A diclofenac epolamine (DE) 1.3% hydroxyethylpyr-
rolidine (Flector®; King Pharmaceuticals Inc., Bristol, TN) 
patch applied locally for 1–2 weeks provides pain relief for 
musculoskeletal conditions such as ankle sprains, tendonitis, 
and knee osteoarthritis, in which analgesia occurs 1 h after 
the first application and is superior to placebo after 3 h. This 
means that the patch provided analgesia in a period in which 
no diclofenac in bloodstream was expected, inferring a local 
action. Serum concentration of diclofenac is reached 9–12 h 
after application of the patch, which suggests the presence 
of reservoir tissue, since the half-life of DE is short. When 
compared to 75 mg taken orally, bioavailability is 1%, with 
few side effects. About 2% of DE is absorbed by the skin and 
a steady state condition is reached within 5.4 h.46
Formulations in diclofenac gel are available for the man-
agement of pain and stiffness in osteoarthritis of the knee, 
such as Voltaren® Gel (diclofenac sodium topical gel 1%; 
Smith & Nephew Healthcare Ltd). Compared to placebo, 
1% diclofenac gel showed improvement in outcomes up to 
4 months after treatment.47,48 Results were similar with 1.5% 
diclofenac gel associated with dimethyl sulfoxide (DMSO), 
a penetration enhancer (Pennsaid®; Mallinckrodt Inc., St. 
Louis, MO).49 In acute musculoskeletal conditions, the DE 
patch controls pain and inflammatory signs within 3–14 days 
when compared to placebo. DE is equivalent to diclofenac 
diethylammonium gel formulation for pain relief.50
Topical NSAIDs can be safer than oral consumption, but 
further studies are needed to compare topical efficacy to other 
administration and delivery methods, such as iontophoresis 
or other physical enhancers.
Ketoprofen
Besides COX inhibition, ketoprofen stabilizes lysosomal 
membranes and antagonizes bradykinin action. With the 
exception of the elderly population, the drug has short half-
life. Side effects are similar to diclofenac, and ketoprofen is 
commercially available as a patch or gel.
Patients with rheumatic diseases or trauma who received 
a ketoprofen patch reported pain relief and functional gain Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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superior to placebo. There is good tolerance, and side effects 
were cutaneous and related to the patch itself, not to the 
active component. Although plasma levels of ketoprofen 
are higher when the drug was administered as a 100-mg 
patch or gel, total bioavailability of the patch was not 
more than 10% of the oral dose. Time release of the patch 
presentation is longer than 24 h, and the drug remains on 
the subjacent tissue of application throughout this period. 
Therefore, the high local concentration and low serum level 
indicated the drug provided local action without systemic 
side effects.51
Gel formulation (Diractin®, formerly IDEA-033; Alpharma 
Inc., Bridgewater, NJ) is recent in the marketplace and is a 
viscous, aqueous formulation based on ultradeformable, 
self-regulating carrier. The ketoprofen patch is noninferior to 
100 mg oral celecoxib for analgesia of knee osteoarthritis.52 
Relief lasted for 12 weeks if applied twice daily.53,54
ibuprofen
Ibuprofen is rapidly absorbed, has renal excretion, and has 
a short half-life. Its good penetration into synovial fluid 
provides antirheumatic effects, which may last after the 
serum concentration decreases. Thanks to greater tolerance 
and less frequent adverse effects in comparison to aspirin 
and indomethacin, ibuprofen has been prescribed for those 
whose gastrointestinal intolerance prevents the use of other 
NSAIDs. Ibuprofen is recommended, especially for relief of 
chronic arthritis and pain following physical exercise.
Studies suggest 5% ibuprofen gel (Nurofen® Gel; Reckitt 
Benckiser, Slough, UK) has comparable efficacy to 400 mg 
oral ibuprofen thrice daily for the treatment of acute pain 
following musculoskeletal injuries.55 A cream presentation 
(Dolgit®; Merck, Whitehouse Station, NJ) demonstrated 
improvement of resting pain and pain during gait among 
patients with knee osteoarthritis and ankle sprains.56
Capsaicin
Capsaicin is derived from hot chilli peppers from the 
genus Capsicum and has a long history of use in medical 
practice. It interacts with sensory afferents via vanilloid recep-
tors VR1, which are cation channels from transient receptor 
potential family. Chronic exposure to capsaicin stimulates 
and desensitizes these channels. Besides, capsaicin depletes 
substance P at nervous afferent endings and transiently 
decreases the density of nervous fibers on the skin. Capsaicin 
is available as 0.025% cream used 3–4 times/day or 8% patch 
for single dose.57 Some of the brand names are Zostrix® (Medi-
cis Pharmaceutical Corporation, Scottsdale, AZ), Qutenza® 
(NeuoguesX, Inc., San Francisco, CA), Capzasin-P® (Chattem 
Labs, Chattanooga, TN), and Zostrix-HP®.
In a systematic review, the efficacy of capsaicin was 
tested in 1556 subjects with musculoskeletal or neuropathic 
pain. Among neuropathic conditions, 57% of them had sig-
nificant analgesia using capsaicin 0.075% in comparison to 
42% of relief with placebo. Among musculoskeletal causes, 
there was a 38% improvement with 0.025% capsaicin patch 
in comparison to 25% relief with placebo. The analgesic 
effect lasted throughout the 4–8 weeks of follow-up.58 Such 
results are similar to the findings of another recent review, 
where improvement in neuropathic pain occurred within 
6–12 weeks with repetitive use of 0.075% capsaicin cream 
or a single patch of 8% capsaicin.59
In placebo-controlled studies, topical capsaicin 0.075% 
demonstrated significant effect on diabetic neuropathy, pos-
therpetic neuropathy, postsurgical pain, and Guillain–Barré 
syndrome.60–62
The principal side effects were localized and included 
burning and erythema, which were worse if applied to moist 
areas. Inhalation of cream may induce respiratory irritation 
and bouts of sneezing. However, if applied repeatedly on the 
same area, burning sensation progressively decreased. Local 
adverse effects were described in one out of three patients, 
and one out of 10 had to withdraw.58 Sensitization is also 
described with allergy to latex.63
Despite the growing use of capsaicin, especially the 
cream presentation, this trend is limited, because four times 
a day application and the resulting burning sensation are 
inconvenient for most of the subjects and thus threaten 
compliance.
Nitroglycerin
Traditionally used in coronary artery diseases, nitrate has 
been demonstrated as potent analgesic and anti-inflammatory 
agent, due to its actions over several cellular systems and 
the central nervous system. Endothelium, macrophages, and 
neutrophils release nitrate in direct proportion to the increase 
in glutamate.
Nitroglycerin is an organic nitrate that acts via a supply 
of free radicals and activation of guanylate cyclase, lead-
ing to intracellular increase of cyclic GMP and modulation 
of phosphodiesterases (PDEs 2, 3, 5) and smooth muscle 
relaxation. Nitrate also activates ATP-sensitive potassium 
channels and peripheral antinociception.
Symptom relief in angina pectoris patients follows 
a decrease of cardiac effort and lower consumption of 
O2 secondary to a decrease in blood pressure. The effect Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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on coronary artery dilation seems to be modest and does 
not justify the symptomatic improvement. Therefore, 
the nitroglycerin effect in alleviating ischemic pain is 
explained by independent mechanisms of vasodilation 
that it induces.57
Nitroglycerin is available in the marketplace as Nitro-Dur® 
(Key Pharmaceuticals, Kenilworth, NJ), Nitrodisc® (Roberts 
Pharmaceuticals, GD Searle & Co., Peapack, NJ), and 
Transderm-Nitro® (Novartis Pharmaceuticals, East Hanover, 
NJ). The two forms of topical glyceryl trinitrate available 
are as follows: 1) Ointment 2% applied to 2.5–5 cm of skin 
each 4–8 h. The effect commences around 30 min and lasts 
up to 6 h. 2) Transdermical disc 2.5–15 mg for 12–16 h/day.   
The absorption is progressive and plasma levels are constant 
the entire day, with peak action occurring between 1 and 
2 h. To avoid tolerance, suspending therapy for 8 h a day is 
recommended.57
Some studies verified the efficiency of nitroglycerin in 
treating rotator cuff lesions. The transdermical disc had a 
tendency to improve acute pain when compared to placebo, 
but several biases prevented a more accurate conclusion 
regarding long-term responses and functional recovery 
following treatment.64 Minor studies evaluated the analgesic 
benefit of nitroglycerin in conditions such as varicose vein 
sclerosis or vulvodynia.
Common side effects are headache, flushing, and palpita-
tions. Serious adverse effects such as hypotension, syncope, 
and transitory ischemic attack are rare. Allergic and/or irritant 
contact dermatitis can also occur. There are also mentions of 
burns secondary to use of microwaves or defibrillators under 
the area where the disc was placed. Patch formulations 
release a high amount of drug, potentiating adverse effects. 
However, measurement of dose is hampered, especially in 
ointments, which become less safe when compared to patch. 
Abrupt suspension of nitroglycerin use can result in acute 
myocardial infarction, peripheral ischemia, and Raynaud’s 
phenomenon.
Since topical nitrates are devoid of renal, gastrointestinal, 
and hematological adverse effects, they can be considered for 
the treatment of local pain, especially in patients contraindi-
cated for NSAID use.63
Other drugs
Other pharmacological agents have been applied topically for 
several types of pain, such as clonidine and gabapentin.65,66 
Some of these are sold over-the-counter, without medical 
prescription. The most recognized agents are described 
below.
Glutamate receptor antagonist
Ketamine is a parenteral anesthetic that provides analgesic 
effects in anesthetic subdoses. It is a noncompetitive 
N-methyl-aspartate (NMDA) receptor antagonist with opioid 
activity. Topical ketamine enhances local anesthetic effects 
of bupivacaine in nociceptive and neuropathic pain. Its 
analgesic effects rely on glutamate receptor activity, voltage-
sensitive calcium channel blockage, interference with opioid 
receptors, and cholinergic and monoaminergic functions.
Indeed, ionotropic glutamate receptors are expressed 
on peripheral afferent nerve terminals and membranes of 
unmyelinated peripheral axons, in proportion to the rate of 
local inflammatory response. In animal models, the increase 
of NMDA and non-NMDA glutamate receptors is associated 
with hyperalgesia and allodynia.67,68
Ketamine hydrochloride is FDA-approved for intra-
venous and intramuscular use and comes in three forms: 
powder, liquid, and tablet. The main trademarks are Ketalar® 
(Pfizer Inc., New York, NY),   Ketanest® (Pfizer Inc), and 
Ketaset® (Fort Dodge Serum Company, Fort Dodge, IA). 
The analgesic response to   intranasal,   rectal, and transdermal 
routes of application have been tested in the treatment of 
refractory nociceptive and   neuropathic pain. Transdermal 
preparations include   hydrogel 1%,   organogel (known as 
Pluronic® lecithin organogel [PLO]. It is a liposomal phos-
pholipid microemulsion), and oil-in-water 0.5% or 1% 
cream or emulsion.
Different vehicles and additives are being tested for the 
development of a transdermal therapeutic system of ketamine 
delivery, aiming to attain the concentration of the drug in 
serum. The hydrogel system provided the highest systemic 
level of circulating ketamine.
Small trials suggest that 0.5%–1% ketamine cream may 
benefit postoperative, sympathetically maintained, and can-
cer pain when applied topically. A case report described the 
efficacy of 0.5% ketamine hydrochloride cream associated 
with 2.5% amitriptyline hydrochloride that gave pain relief 
and improvement of quality of life in patients suffering from 
idiopathic proctodynia.69 Because ketamine is a phencycli-
dine analog and leads to psychomimetic effects, it is not 
used routinely as an anesthetic, although there has been a 
dangerous increase in recreational use of ketamine.
Alpha-adrenoceptor antagonists
Clonidine hydrochloride is available in 0.1, 0.2, and 0.3 mg 
tablets, generally for oral treatment of systemic hyperten-
sion (Catapres®; Boehringer-Inghelm Phamaceuticals Inc., 
Ridgefield, CT); however, extensive analgesic use of oral Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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clonidine is limited by centrally mediated side effects (seda-
tion, hypotension, and rebound hypertension).
When applied topically as creams or patches (Catapres 
TTS®), it is a potent antinociceptive agent that produces 
central and peripheral analgesic effects by blocking the 
emerging pain signals at peripheral terminals via alpha-2 
adrenoceptors without producing the undesirable central side 
effects observed in systemic administration. Nevertheless, 
there are reports of symptomatic worsening of hyperalgesia 
in the presence of peripheral nervous damage.
It has been used to control hyperalgesia present in complex 
regional pain syndromes, likely due to the reduction of pre-
synaptic norepinephrine release from sympathetic nerves.65 
This might explain the worsening of mechanical hyperalgesia 
that sympathetically maintained pain patients present when 
submitted to localized injection of norepinephrine.70
Topical administration of clonidine in mice was found to 
elicit analgesia, and the response suggests that the actions of 
clonidine are locally mediated. The ineffectiveness of topical 
ketamine to block topical clonidine antinociceptive tolerance 
suggests that peripheral NMDA receptors do not mediate 
local clonidine antinociceptive tolerance.
The transdermal therapeutic system for clonidine delivery 
consists of a multilayered film containing the active agent, 
designed for constant drug release over 7 days.
The system is 3.5 cm2 thick, 7.0 × 10.5 cm2, composed 
of four consecutive layers: 1) backing layer of polyester and 
aluminum, 2) drug reservoir of clonidine, mineral oil, poly-
isobutylene, and colloidal silicon dioxide, 3) microporous 
polypropylene membrane that controls the rate of delivery, 
and 4) adhesive formulation of clonidine, mineral oil, 
polyisobutylene, and colloidal silicon dioxide.
Cannabinoids
Cannabinoids (delta8-tetrahydrocannabinol [delta8-
THC], cannabidiol [CBD], and cannabinol [CBN]), extracted 
from Cannabis sativa L, act at peripheral sites and yield 
analgesia through the action on CB1 and CB2 receptors. 
Dorsal root ganglia cells contain mRNA for CB1 receptors. 
Additionally, CB1 receptor agonists inhibit nerve growth 
factor and calcitonin gene-related peptide release.71 Local 
analgesic actions of agonists for CB2 receptors include the 
inhibition of mast cell function and inflammatory pain.
The topical administration of selective cannabinoid 
receptor agents has been demonstrated to have analgesic 
effects in animal models of inflammatory and neuropathic 
pain (formalin, carrageenan hyperalgesia, and partial nerve 
injury), especially for the control of breakthrough pain.
Transdermal cannabinoids were developed to blunt the 
side effects related to dose peaks and have a controlled 
release of active drug over a period of days. Intranasal can-
nabinoid sprays are used as a low-dose adjuvant to patches, 
and to warrant rapid absorption for systemic effects. Indeed, 
coadministration of agonists for both CB1 and CB2 recep-
tors tends to potentiate analgesia. A 50/50 mixture of CBN 
and CBD in the form of transmucosal spray benefited 
central pain in multiple sclerosis.72 These findings support 
the development of other topical formulations or combi-
nations of cannabinoids that could be devoid of central 
adverse effects.
These substances require further clinical trials for safety 
analysis before gaining a foothold in clinical practice. 
Central actions are still the main concern for this class of 
agents. In addition, transporting these drugs into human 
skin, opportunities for combined therapies, and appropriate 
vehicles need to be studied to improve transdermal delivery 
systems.
Medication adherence
Adherence is defined as the extent to which the patient’s 
medication consumption matches the prescribed regimen. 
The impact of nonadherence varies across chronic illnesses, 
from minimal to significant. In many diseases, poor com-
pliance to medication intake and medical advice threatens 
treatment outcomes.
Several classes of correlates of adherence to long-term 
medication regimens have recently been identified and can 
be separated into groups: patient (depression and substance 
abuse history), contextual (social support and socioeconomic 
status), clinician communication skills (patient–clinician 
relationship), disease (chronicity and symptom burden), 
health care delivery (wait for appointment and medications), 
and treatment regimen factors.73 Analysis of treatment adher-
ence among chronic diseases fails and results are conflicting, 
due to substantial methodological variability of measurement. 
Although this is an impediment, it is possible to detect the 
primary factors of therapeutic regimen that directly influence 
patient adherence.73
Several studies suggest the advantage of simplification of 
the regimen complexity, usually by decreasing the pill burden 
and dosage, while a few conclude that there is no systematic 
difference between the effects of changing doses and other 
behavioral interventions. They researches argue that while the 
half-life of some drugs favors their management and relieves 
the impact of consuming several intakes per day, they do 
not always ensure patients’ compliance. The World Health Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
21
Topical analgesics: efficacy and adherence
Organization claims the main barriers to adherence related 
to regimen factors are high dosing and side effects.
For short-term treatment or seasonal diseases,74,75 straight-
forward strategies and delivery of information to patients 
increased compliance, but the results are not consistent 
across all studies.
For long-term treatment of chronic diseases, a combina-
tion of strategies such as providing detailed instructions, close 
follow-up, reminders, rewards for successful compliance, 
family therapy, psychological therapy, crisis intervention, 
reinforcement, supportive care, and telephone follow-up 
seek to improve adherence and clinical outcomes, but they 
lack efficacy, despite major effort and applied resources.76 
However, a review of the impact of dosing schedules in 
chronic illness pointed out that adherence was higher 
among patients taking once-daily medications compared 
to thrice or more frequent dosing, suggesting that simpler 
dosing regimens increase adherence.77 Indeed, the increasing 
availability of new formulations of medications, including 
extended-release and modified-release products, and formu-
lations requiring weekly dosing may ease the regimens.
The challenges of treatment adherence have been investi-
gated in several diseases, and each condition needs a different 
strategy, as shown in Table 1.
In acute pain, the symptomatic, episodic feature of the dis-
ease minimizes issues related to compliance. They are not the 
focus of recent research studies. Studies focused on chronic pain 
treatment are concerned with the appropriate dose to achieve 
analgesia while avoiding negative outcomes such as addiction, 
rather than checking adherence and dosing relationships or 
compliance. Old studies point out that, different from other non-
painful diseases, chronic pain patients preferred multiple doses 
daily for analgesics, suggesting the worry that their pain would 
be undertreated if fewer doses were taken.88 Because the major-
ity of studies on chronic diseases indicate dosing simplification 
for better patient adherence, there is a need for new studies to 
be conducted in order to verify the findings above.
When chronic pain patients are asked about those which 
are the least acceptable adverse experiences related to a 
drug, they report central nervous system impairments.89 
Topical agents are devoid of most systemic effects, but can 
only be used in specific conditions, and their effectiveness 
must be further elaborated. Therefore, for chronic or acute 
localized peripheral painful syndromes, topical preparations 
may contribute to patient adherence, due to low incidence of 
collateral effects and minimal number of daily applications.
Conclusion
Although only a small number of topical agents are available 
for use in peripheral and local conditions, increasing evidence 
supports the efficacy of such preparations for the relief of 
nociceptive or neuropathic pain. Overall, topical preparations 
have a good safety profile, which might benefit the elderly and 
pediatric populations and those presenting with intolerance to 
traditional treatments. Nevertheless, the quality of most of the 
studies examined is compromised by methodological heteroge-
neity, such as small sample size, and lack of control groups. It 
is also worth noting that this is not a systematic review of each 
Table 1 Brief description of different strategies to increase treatment adherence in selected diseases
   Patient awareness of breast cancer has increased, and physicians are required to provide information regarding treatment goals and adverse 
effects of drugs, which are frequent and disabling. These issues influence compliance.78
   Among patients with cardiac failure, the main predictor for cardiac rehabilitation was the physician’s endorsement of the effectiveness of 
program. Adherence increased when patients were actively referred, educated, highly self-motivated, and when programs were easily accessible.79
   The major barriers for a good glycemic control include low efficacy of oral hypoglycemic drugs, fear of hypoglycemia, issues related to convenience 
of treatment (subcutaneous route, invasive blood sugar monitoring), poor access to health services, and lifestyle, leading to low adherence.80
   educational sessions, psychotherapeutic interventions, and phone prompts in community psychiatric services increase adherence of psychotic 
patients.81
   Factors associated with poor treatment adherence among patients undergoing renal replacement therapy or under dialysis are frequent dosing, 
patient’s perception of treatment benefits, poor patient–physician communication, lack of motivation, low socioeconomic background. Strategies 
for compliance are not well established, but some are suggested: treatment regimen simplification, establishing a partnership with the patient, and 
education.82
   The most striking barrier to medication adherence in multiple sclerosis is forgetfulness to take pills, coping with adverse effects, and perceived 
lack of efficacy. Validated strategies include good provider–patient relationship, continuous education, and reinforcement regarding the benefit of 
treatment.83
   Nonadherence of chronic obstructive pulmonary disease in 40%–60% as opposed to asthmatic patients, who adhere to inhalers and rescue 
medication. Economic factors and health beliefs influence device selection.84
   Long-term adherence for asymptomatic conditions such as arterial hypertension is 50%. For these patients, adverse effects related to 
antihypertensive therapies and costs threaten treatment adherence.85 The most commonly used method to increase in compliance in 
dyslipidemia86 and hypertension87 is dosing schedule modification from twice to once a day dosing.Journal of Pain Research 2011:4 submit your manuscript | www.dovepress.com
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class of topical drug, which prevents a definitive interpretation 
of the evidence regarding topical drug efficacy and the compli-
ance of patients submitted to these preparations.
Despite the paucity of data, the intervention most 
likely to result in optimal adherence for the majority of 
patients is simplification of drug regimens. Pharmaceutical 
companies should be encouraged to develop medications 
that simplify treatment regimes, augment compliance, 
and reduce adverse effects. Patients would have a greater 
spectrum of treatment options if extended release com-
pounds were developed to provide alternative routes of 
administration, such as topical delivery. The potential 
advantage of topical analgesic drugs is the minimization 
of both the presence of central side effects and the loss of 
efficacy of complex treatment regimens. The opportunity 
to develop topical drugs would also benefit pediatric, frail, 
and elderly populations.
However, due to the absence of specific compliance 
and adherence studies comparing topical treatment versus 
traditional routes in pain management, the role of topical 
preparations in patient adherence remains obscure.
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